HomeInvestingOptionsMRNA, PFE: How Biotech Will Perform In A Post-Covid World

MRNA, PFE: How Biotech Will Perform In A Post-Covid World

Moderna (MRNA) will lose money in 2023 because they are projecting $6B in R&D and other expenses, says Brad Loncar. He discusses biotech stocks. He notes that companies are focusing on vaccines for other issues like RSV to help make up for lost Covid sales. He then goes over the outlook for vaccine maker, as well as how biotech stocks will perform in a post-Covid world. Tom White then joins to demonstrate example trades using Moderna (MRNA) and Pfizer (PFE). Tune in to find out more about the stock market today.

Morning Trade Live

09 Mar 2023

SHARE

ON AIR
4:00 am
Fast Market
replay
12:00 am
Fast Market
REPLAY
education
1:00 am
Your First Trade
REPLAY
1:30 am
Next Gen Investing
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Trading 360
REPLAY
ON AIR
4:00 am
Fast Market
REPLAY
5:00 am
Next Gen Investing
REPLAY
education
6:00 am
Your First Trade
REPLAY
6:30 am
Trading 360
REPLAY
7:30 am
Fast Market
REPLAY
8:30 am
Next Gen Investing
REPLAY
9:30 am
Market Overtime
REPLAY
10:00 am
Trading 360
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Your First Trade
REPLAY
1:30 pm
Trading 360
REPLAY
2:30 pm
Fast Market
REPLAY
3:30 pm
Next Gen Investing
REPLAY
4:30 pm
Market Overtime
REPLAY
5:00 pm
Trading 360
REPLAY
6:00 pm
Fast Market
REPLAY
7:00 pm
Next Gen Investing
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Trading 360
REPLAY
9:30 pm
Fast Market
REPLAY
10:30 pm
Next Gen Investing
REPLAY
education
11:30 pm
Your First Trade
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now